1) “We keep hearing about the 30-60% savings of drug discovery and development work in China and India.
Is it really working out that way for MNCs?”
2) “MNCs seem to be making much bigger investments in captive R&D centers in China than they are in India.
Why is that? “
3) “In most every other industry, intellectual property is a much bigger problem in China than in India. But in pharmaceuticals, it is the other way around.
Please explain.”
4) “How are these risk-sharing partnerships with Indian CROs working out in practice?
In general, are they delivering as promised to MNCs? Is the quality of their work as good as advertised? Same question for the Chinese CROs.”
5) “The health care systems are evolving in both India and China. India is mainly out-of-pocket and is grossly underserved. In China, drugs are distributed through hospitals and cost can be very expensive for the average person.
How will these systems evolve, and what does that mean for big pharmaceutical companies?”
6)
“If you aren't doing a lot in India or China now, is it too late? Are is there an advantage in being a late mover?”
7) More pharma MNCs are turning their attention to "smaller" diseases and niche markets, rather than focusing exclusively on megabillion blockbusters. Will this continue, and are the lower drug discovery costs in China and India helping this trend?
8) Traditional Chinese Medicine (TCM) in China and ayurvedics in India are big markets.
Why is it we see very little interest or developments on this from Big Pharma? Can you explain?
